

Cite this as: Yu WU, Guomin JU, Xueyu ZHOU, Jian WU, Shusen ZHENG, Chuanhui PENG.

Targeting *WTAP* sensitizes hepatocellular carcinoma to sorafenib by inhibiting the ERK signaling pathway. *Journal of Zhejiang University-SCIENCE B*, 2026, 27(3):310-320.

<https://doi.org/10.1631/jzus.B2500191>

Targeting *WTAP* sensitizes hepatocellular carcinoma to sorafenib by inhibiting the ERK signaling pathway


Key words: Wilms' tumor 1-associated protein (WTAP); Sorafenib resistance; Extracellular signal-regulated kinase (ERK) pathway; Hepatocellular carcinoma (HCC)

Research Summary


This study identifies WTAP as a key driver of sorafenib resistance in hepatocellular carcinoma (HCC) and proposes a novel combination therapy.:



- WTAP knockdown **enhances** sorafenib sensitivity in vitro and in vivo.
- WTAP promotes resistance by activating the **ERK** signaling pathway.
- Targeting WTAP **synergizes** with sorafenib to suppress tumor growth.



Proliferation of cancer cells



Innovation points

- **Identification** of WTAP as a novel critical regulator of sorafenib resistance in HCC.
- **Integration** of multi-modal approaches to delineate the WTAP-ERK resistance axis.
- **Proposal** of targeting WTAP as a promising strategy to overcome sorafenib resistance and enhance therapeutic efficacy in HCC.